Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
| ▸ | MOK | Q9UQ07 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19429857 | 0.98 | PRMT6 (0.39) | PRMT6POLBMOKTDP1WNK1 | |
| SCHEMBL19429973 | 0.92 | PRMT6 (0.48) | PRMT6POLBAOC3MOK | |
| SCHEMBL19430232 | 0.91 | AOC3 (0.40) | POLBCYP2C9AOC3TDP1WNK1 | |
| SCHEMBL19430109 | 0.89 | PRMT6 (0.37) | PRMT6MOKWNK1 | |
| SCHEMBL19429860 | 0.89 | SMN1; SMN2 (0.44) | PRMT6KMT2A | |
| SCHEMBL19429963 | 0.89 | PRMT6 (0.37) | PRMT6AOC3MOKWNK1 | |
| SCHEMBL19430299 | 0.88 | PRMT6 (0.36) | PRMT6MOKWNK1 | |
| SCHEMBL19429853 | 0.88 | AOC3 (0.41) | POLBAOC3TDP1WNK1KMT2A | |
| SCHEMBL19430139 | 0.87 | PRMT6 (0.41) | PRMT6AOC3MOK | |
| SCHEMBL19429867 | 0.83 | AOC3 (0.39) | POLBAOC3TDP1WNK1TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT6 4/4885POLB 2003/4885CYP2C9 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.